| Caroline Cassling, MD | |
|
84 Marginal Way Ste 900, Portland, ME 04101-2476 | |
| (207) 874-2445 | |
| (207) 523-8598 |
| Full Name | Caroline Cassling |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 84 Marginal Way Ste 900, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760860787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD23066 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermed Pa | 5092605261 | 149 |
News Archive
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday by voice vote approved a $631 billion fiscal year 2009 Labor-HHS-Education appropriations bill, CQ Today reports.
University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).
› Verified 8 days ago
| Entity Name | Intermed Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467422733 PECOS PAC ID: 5092605261 Enrollment ID: O20040319000548 |
News Archive
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday by voice vote approved a $631 billion fiscal year 2009 Labor-HHS-Education appropriations bill, CQ Today reports.
University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).
› Verified 8 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday by voice vote approved a $631 billion fiscal year 2009 Labor-HHS-Education appropriations bill, CQ Today reports.
University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).
› Verified 8 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday by voice vote approved a $631 billion fiscal year 2009 Labor-HHS-Education appropriations bill, CQ Today reports.
University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Caroline Cassling, MD 100 Gannett Dr Ste C, South Portland, ME 04106-5900 Ph: (207) 874-2445 | Caroline Cassling, MD 84 Marginal Way Ste 900, Portland, ME 04101-2476 Ph: (207) 874-2445 |
News Archive
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
The Senate Appropriations Labor, HHS, Education and Related Agencies Subcommittee on Tuesday by voice vote approved a $631 billion fiscal year 2009 Labor-HHS-Education appropriations bill, CQ Today reports.
University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).
› Verified 8 days ago
Carol M Vaughan, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 84 Marginal Way, Suite 900, Portland, ME 04101 Phone: 207-874-2445 Fax: 207-523-8598 | |
Toby M Fitzgerald, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 887 Congress St Ste 200, Portland, ME 04102 Phone: 207-771-5549 Fax: 207-771-7834 | |
Dr. Edward Bumno Yoon, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 895 Washington Ave, Portland, ME 04103 Phone: 207-791-3888 | |
Dr. Kathryn G Wadland, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 195 Fore River Pkwy, Suite 440, Portland, ME 04102 Phone: 207-553-6920 Fax: 207-553-6940 | |
Anne Marie Van Hengel, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 84 Marginal Way, Suite 900, Portland, ME 04101 Phone: 207-874-2445 Fax: 207-523-8598 | |
Dr. Debra K Sepulveda, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 Fax: 207-662-6219 | |
Mary Anne Carroll, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Maine Medical Center, 22 Bramhall Street, Portland, ME 04102 Phone: 207-662-0111 |